rchop
chemotherapi
compos
rituximab
cyclophosphamid
adriamycin
vincristin
prednisolon
might
increas
risk
pneumocysti
pneumonia
patient
nonhodgkin
lymphoma
estim
point
preval
pneumocysti
pneumonia
nonhodgkin
lymphoma
patient
accord
number
rchop
cycl
investig
whether
cytoreduct
chemotherapi
associ
pneumocysti
pneumonia
develop
retrospect
establish
cohort
patient
receiv
rchop
nonhodgkin
lymphoma
institut
use
cohort
estim
incid
rate
point
preval
definit
probabl
pneumocysti
pneumonia
assess
factor
associ
pneumocysti
pneumonia
develop
sever
clinic
variabl
includ
absolut
neutrophil
lymphocyt
count
time
nonhodgkin
lymphoma
diagnosi
last
rchop
cycl
administ
compar
patient
without
pneumocysti
pneumonia
patient
cohort
patient
diagnos
definit
probabl
pneumocysti
pneumonia
respect
overal
incid
definit
definit
plu
probabl
pcp
nhl
patient
receiv
rchop
ci
ci
respect
correspond
ci
ci
per
person
mani
case
pneumocysti
pneumonia
develop
administr
fourth
rchop
cycl
howev
statist
differ
pneumocysti
pneumonia
preval
patient
receiv
four
cycl
rchop
fewer
higher
absolut
neutrophil
count
vs
mm
p
associ
pneumocysti
pneumonia
develop
last
rchop
cycl
absolut
lymphocyt
count
time
nhl
diagnosi
contrari
expect
pneumocysti
pneumonia
frequent
complic
rchop
treatment
nonhodgkin
lymphoma
cytoreduct
rchop
might
risk
factor
pneumocysti
pneumonia
develop
univers
prophylaxi
pneumocysti
pneumonia
rchop
treatment
could
strongli
recommend
pneumocysti
jirovecii
pneumonia
pcp
one
major
infecti
complic
chemotherapi
patient
without
human
immunedefici
viru
hiv
infect
system
corticosteroid
usag
identifi
predispos
factor
pcp
previou
studi
also
known
rituximab
usag
might
risk
factor
pcp
develop
addit
case
seri
patient
solid
tumor
show
cytoreduct
chemotherapi
without
corticosteroid
could
suffici
predispos
condit
pcp
rchop
regimen
therapi
nonhodgkin
lymphoma
nhl
consist
rituximab
cyclophosphamid
adriamycin
vincristin
prednisolon
see
two
kind
regimen
could
increas
risk
pcp
develop
includ
rituximab
prednisolon
addit
risk
could
increas
administr
sever
cycl
rchop
regimen
cytoreduct
might
progress
durat
corticosteroid
usag
lengthen
consequ
repeat
chemotherapi
inde
previou
report
show
antilymphocyt
count
alc
decreas
accord
number
cycl
rchop
therapi
base
rational
readili
infer
pcp
might
develop
often
patient
nhl
treat
rchop
incid
pcp
could
increas
accord
repeat
cycl
rchop
despit
background
welldescrib
studi
show
incid
pcp
patient
receiv
rchop
use
nhl
treatment
develop
pcp
notabl
previou
studi
address
efficaci
rchop
nhl
case
seri
pcp
patient
nhl
report
studi
consid
issu
pcp
develop
patient
receiv
rchop
nhl
howev
studi
includ
patient
pcp
confirm
biopsi
direct
immunofluoresec
assay
addit
show
trend
point
preval
pcp
develop
accord
number
cycl
rchop
therapi
therefor
estim
point
preval
pcp
patient
nhl
accord
number
cycl
rchop
investig
whether
low
alc
associ
pcp
develop
verifi
hypothesi
pcp
frequent
develop
nhl
patient
treat
rchop
point
preval
pcp
increas
accord
number
cycl
alc
marker
cytoreduct
result
repeat
chemotherapi
associ
pcp
develop
studi
perform
asan
medic
center
tertiari
care
teach
hospit
seoul
korea
search
electron
medic
record
patient
receiv
rchop
regimen
treatment
nhl
retrospect
establish
cohort
nhl
patient
administ
rchop
regimen
januari
decemb
patient
less
year
old
exclud
patient
cohort
follow
least
month
rchop
regimen
center
consist
mgm
rituximab
mgm
cyclophosphamid
mgm
doxorubicin
mg
vincristin
day
mg
prednison
day
administ
everi
week
cycl
base
nhl
statu
clinician
judgment
data
demograph
age
gender
clinic
ann
arbor
stage
patholog
nhl
variabl
retrospect
collect
inform
rchop
therapi
number
interv
cycl
record
also
note
whether
patient
receiv
prior
antipneumocysti
prophylaxi
laboratori
result
absolut
neutrophil
count
anc
alc
lactat
dehydrogenas
ldh
level
time
nhl
diagnosi
administr
last
rchop
also
record
first
search
patient
posit
test
result
immunofluoresc
assay
pcp
use
bronchoalveolar
lavag
bal
sampl
within
cohort
among
respiratori
symptom
radiolog
find
compat
pcp
diagnos
definit
pcp
broncholalveolar
lavag
perform
fiberopt
bronchoscop
use
standard
techniqu
direct
immunofluoresc
assay
detect
p
jirovecii
perform
use
commerci
avail
murin
monoclon
antibodi
label
fluorescein
isothiocyan
react
human
rodent
pneumocysti
cyst
trophozoit
accord
manufactur
instruct
light
diagnost
tm
pneumocysti
carinii
dfa
kit
millipor
billerica
usa
secondli
search
patient
receiv
antipneumocysti
regimen
therapeut
dose
among
follow
condit
consid
probabl
pcp
symptom
fever
cough
dyspnea
radiolog
find
compat
pcp
definit
caus
pneumonia
event
happen
kind
salvag
chemotherapi
exclud
purpos
studi
estim
point
preval
pcp
patient
receiv
rchop
regimen
clinic
characterist
time
onset
pcp
first
last
rchop
cycl
sever
pcp
treatment
durat
adjunct
steroid
usag
intens
care
unit
admiss
mechan
ventil
mortal
investig
classif
sever
pcp
base
pao
breath
room
air
alveolararteri
oxygen
differ
aado
prior
first
bronchoscopi
mild
pcp
pao
mmhg
aado
moder
pcp
pao
mmhg
aado
sever
pcp
pao
mmhg
aado
laboratori
result
bal
white
blood
count
creactiv
protein
also
collect
statist
analys
perform
use
spss
version
spss
chicago
il
usa
data
present
median
score
interquartil
rang
iqr
parenthes
incid
rate
pcp
estim
divid
number
pcp
case
cohort
number
personcycl
rchop
atrisk
overal
cohort
point
preval
estim
proport
patient
pcp
cycl
rchop
therapi
confid
interv
ci
incid
rate
preval
estim
base
poisson
distribut
categor
variabl
compar
use
fisher
exact
test
continu
variabl
analyz
mannwhitney
u
test
data
normal
distribut
patient
cohort
regardless
pcp
develop
anc
alc
ldh
valu
time
nhl
diagnosi
last
rchop
cycl
compar
pair
test
analysi
covari
use
compar
extent
alc
decreas
patient
without
pcp
test
twotail
differ
consid
signific
p
studi
period
patient
receiv
rchop
treatment
nhl
diffus
larg
b
cell
lymphoma
dlbl
common
patholog
type
patholog
type
mantl
cell
lymphoma
mcl
follicular
lymphoma
margin
zone
lymphoma
mucosaassoci
lymphoid
tissu
lymphomatoid
granulomatosi
total
patient
treat
six
cycl
rchop
definit
pcp
happen
receiv
six
cycl
receiv
seven
cycl
receiv
eight
cycl
addit
patient
receiv
cycl
rchop
respect
hand
total
patient
treat
six
cycl
rchop
definit
probabl
pcp
happen
receiv
six
cycl
receiv
seven
cycl
receiv
eight
cycl
addit
patient
receiv
cycl
rchop
respect
among
patient
enrol
cohort
patient
diagnos
definit
probabl
pcp
respect
probabl
patient
search
follow
process
retrospect
found
patient
receiv
antipneumocysti
regimen
cohort
patient
patient
receiv
less
day
antipneumocysti
regimen
physician
judg
event
like
p
jirovecii
infect
patient
sign
symptom
pcp
patient
compat
radiolog
find
patient
receiv
kind
salvag
chemotherapi
event
happen
patient
definit
caus
interstiti
pneumonia
cmv
influenza
coronaviru
diagnos
cultur
bal
specimen
patient
neg
dfa
result
patient
receiv
tmp
smz
treatment
maltophilia
two
patient
empir
receiv
tmpsmx
fever
subsid
nevertheless
broadspectrum
antibiot
usag
consequ
patient
suspect
pcp
receiv
tmpsmx
treat
pcp
patient
bal
done
patient
neg
result
dfa
document
result
biopsi
bal
fluid
analysi
favor
diagnosi
druginduc
interstiti
lung
diseas
individu
clinic
characterist
patient
shown
supplement
figur
tabl
show
point
preval
rate
pcp
cycl
rchop
chemotherapi
overal
incid
definit
definit
plu
probabl
pcp
nhl
patient
receiv
rchop
ci
ci
respect
correspond
ci
ci
per
person
case
definit
pcp
occur
administr
four
cycl
rchop
howev
statist
differ
pcp
preval
patient
receiv
four
cycl
rchop
receiv
fewer
four
cycl
vs
probabl
pcp
includ
analysi
ratio
lower
patient
event
probabl
pcp
administr
four
cycl
rchop
tabl
show
comparison
clinic
variabl
patient
without
pcp
compar
patient
without
definit
pcp
none
variabl
show
statist
signific
differ
howev
compar
patient
without
either
definit
probabl
pcp
higher
anc
vs
p
found
statist
signific
patient
definit
probabl
pcp
without
median
anc
alc
ldh
time
last
rchop
administr
iqr
iqr
iul
iqr
patient
probabl
pcp
respect
expect
alc
time
nhl
diagnosi
last
cycl
rchop
statist
differ
patient
without
pcp
mean
alc
time
last
rchop
cycl
lower
time
nhl
diagnosi
vs
mm
p
pair
test
patient
cohort
extent
alc
decreas
statist
differ
patient
without
definit
pcp
statist
differ
shown
regardless
includ
probabl
pcp
patient
analysi
one
aim
studi
determin
incid
rate
pcp
nhl
patient
receiv
rchop
chemotherapi
studi
includ
patient
definit
probabl
pcp
among
patient
receiv
rchop
nhl
knowledg
largest
studi
investig
incid
rate
pcp
nhl
treat
rchop
overal
incid
rate
definit
pcp
studi
cohort
seem
lower
previou
studi
differ
might
aris
differ
interv
rchop
cycl
previou
studi
interv
rchop
cycl
day
wherea
patient
studi
receiv
rchop
regimen
interv
day
cycl
fact
studi
similar
result
report
pcp
incid
rate
patient
receiv
rchop
cycl
interv
day
low
incid
rate
pcp
studi
support
previou
observ
pcp
develop
frequent
patient
receiv
rchop
interv
interv
anoth
aim
studi
show
point
preval
pcp
base
number
rchop
cycl
studi
case
definit
pcp
develop
fourth
cycl
rchop
consist
previou
result
review
case
seri
previou
studi
found
case
pcp
occur
patient
receiv
four
cycl
rchop
includ
case
probabl
pcp
howev
proport
lower
differ
might
come
possibl
patient
probabl
pcp
might
actual
pcp
say
viral
pneumonia
drugrel
lung
diseas
resembl
clinic
manifest
pcp
might
happen
earlier
cycl
rchop
result
impli
repeat
rchop
cycl
might
increas
suscept
patient
nhl
pcp
repeat
rchop
shown
chang
host
immun
statu
deplet
lymphocyt
trial
base
find
show
low
alc
associ
pcp
develop
patient
nhl
howev
previou
studi
includ
crosssect
comparison
alc
valu
time
nhl
diagnosi
patient
without
pcp
suffici
confirm
valid
alc
predict
pcp
impact
rchop
valu
alc
reflect
analysi
therefor
compar
alc
time
nhl
diagnosi
last
rchop
treatment
contrast
previou
studi
fail
prove
alc
associ
pcp
develop
alc
statist
differ
patient
without
pcp
either
time
nhl
diagnosi
last
cycl
rchop
furthermor
although
alc
time
last
rchop
chemotherapi
lower
time
nhl
diagnosi
extent
decreas
statist
differ
patient
without
pcp
hiv
infect
patient
total
number
associ
pcp
develop
use
alc
surrog
indic
count
may
appropri
set
particularli
cell
count
known
recov
faster
count
thu
lack
associ
alc
could
explain
alc
might
reliabl
tool
predict
pcp
develop
unexpectedli
higher
anc
associ
develop
definit
probabl
pcp
although
valid
analysi
case
definit
pcp
studi
show
kind
associ
higher
anc
might
come
preced
inflammatori
chang
clinic
manifest
pcp
appear
addit
probabl
pcp
might
druginduc
interstiti
pneumon
could
make
anc
higher
find
suggest
cytoreduct
rchop
might
risk
factor
pcp
develop
statement
confirm
howev
case
probabl
pcp
includ
analysi
current
unclear
whether
antipneumocysti
prophylaxi
necessari
patient
receiv
rchop
base
follow
reason
antipneumocysti
prophylaxi
patient
could
suggest
rchop
might
increas
risk
pcp
develop
might
help
differenti
pcp
druginduc
lung
interstiti
diseas
sinc
breakthrough
develop
pcp
seem
unlik
happen
frequent
word
might
say
diagnosi
druginduc
lung
interstiti
diseas
seem
favor
patient
receiv
antipneumocysti
prophylaxi
suffer
interstiti
pneumon
despit
obstacl
make
clinician
hesit
start
prophylaxi
first
incid
rate
definit
pcp
consider
high
although
almost
patient
cohort
receiv
antipneumocysti
prophylaxi
rate
pcp
develop
low
expert
assert
antipneumocysti
prophylaxi
necessari
situat
incid
rate
pcp
greater
second
studi
develop
definit
pcp
associ
bad
prognosi
fact
one
patient
die
result
definit
pcp
suggest
late
start
antipneumocysti
therapi
symptom
pcp
manifest
long
patient
cautious
observ
lastli
one
import
side
effect
tmp
smx
use
antipneumocysti
prophylaxi
bone
marrow
suppress
crucial
side
effect
disturb
normal
cours
nhl
therapi
henc
studi
estim
costeffect
antipneumocysti
prophylaxi
patient
receiv
rchop
use
nhl
perform
limit
studi
first
possibl
incid
rate
pcp
might
underestim
studi
retrospect
clinician
sometim
empir
administ
antipneumocysti
regimen
without
diagnost
test
patient
suspect
pcp
addit
sensit
method
pcp
betadglucan
use
diagnosi
pcp
avoid
error
lower
estim
pcp
incid
ad
analysi
probabl
pcp
overal
incid
definit
probabl
pcp
less
patient
receiv
rchop
regimen
henc
statement
seem
still
consider
studi
howev
almost
patient
receiv
rchop
everi
three
week
therefor
statement
would
applic
center
rchop
administ
everi
two
week
anoth
limit
candid
variabl
fulli
investig
determin
risk
factor
pcp
develop
conclus
contrari
expect
pcp
frequent
complic
rchop
treatment
nonhodgkin
lymphoma
therefor
univers
prophylaxi
p
jirovecii
rchop
treatment
could
strongli
recommend
welldesign
studi
address
costeffect
antipneumocysti
prophylaxi
patient
nhl
treat
rchop
follow
justifi
usag
antipneumocysti
regimen
prophylaxi
addit
could
conclud
associ
cytoreduct
pcp
develop
trial
carri
identifi
predict
factor
pcp
develop
patient
